CFO of $AEVA Sells 10,123 Shares in Insider Transaction

The Chief Financial Officer of $AEVA, Saurabh Sinha, recently sold 10,123 shares of the company on 07-01-2025, totaling an estimated $314,702, according to a recent SEC filing. This sale represented about 1.0% of their class of stock shares, leaving them with 992,949 shares of $AEVA stock.

Over the past 6 months, $AEVA insiders have been actively trading the company’s stock on the open market, with a total of 29 transactions. Among these transactions, 6 were purchases, while 23 were sales. Notable instances include CAPITAL LLC SYLEBRA’s 6 purchases, acquiring 5,849,249 shares, and MINA REZK, the Chief Technology Officer, who made 13 sales of 720,000 shares. Additionally, SOROUSH SALEHIAN DARDASHTI, the Chief Executive Officer, made 5 sales of 450,000 shares, HRACH SIMONIAN made 3 sales of 100,000 shares, and SAURABH SINHA sold 10,123 shares. Further, STEPHEN PAUL ZADESKY divested 14,851 shares.

On the hedge fund activity front, 45 institutional investors increased their holdings of $AEVA stock, while 33 reduced their positions in the most recent quarter. Notable moves include SYLEBRA CAPITAL LLC adding 5,849,249 shares (a 56.4% increase) to their portfolio in Q1 2025, and ADAGE CAPITAL PARTNERS GP, L.L.C. shedding 1,633,708 shares (a 53.8% decrease) in the same period. Other significant transactions included JANE STREET GROUP, LLC removing 648,942 shares, D. E. SHAW & CO., INC. adding 154,515 shares, WALLEYE CAPITAL LLC adding 136,325 shares, BANK OF AMERICA CORP /DE/ adding 133,973 shares, and UBS GROUP AG adding 102,427 shares.

Regarding analyst ratings, Wall Street analysts have provided feedback on $AEVA in recent months, with 2 firms issuing buy ratings. Roth Capital gave a “Buy” rating on 06/16/2025, while Oppenheimer issued an “Outperform” rating on 05/15/2025. Multiple price targets have been set for $AEVA by analysts, with the median target at $9.0. Suji Desilva from Roth Capital set a target price of $30.0 on 06/16/2025, while analysts from Oppenheimer and Morgan Stanley set targets of $9.0 and $5.22, respectively.

It is important to note that this article is not offering financial advice, and readers should refer to Quiver Quantitative’s disclaimers for further information.